Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3976469 | Brachytherapy | 2016 | 11 Pages |
Abstract
EBRT plus brachytherapy is associated with a modest OS improvement compared with brachytherapy alone in this population-based analysis. Although this benefit appears statistically significant, the relatively small difference in OS raises the question of overall clinical benefit with combined modality RT for intermediate-risk prostate cancer, given the potential increased risk for toxicities. Future results from Radiation Therapy Oncology Group 0232 should provide further insight on this topic.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Arya Amini, Bernard L. Jones, Matthew W. Jackson, Chad G. Rusthoven, Paul Maroni, Brian D. Kavanagh, David Raben,